Phase II trial of mitoguazone in patients with advanced squamous cell carcinoma of the head and neck

D. J. Perry, S. M. Crain, M. D. Weltz, J. P. Wilson, R. K. Davis, P. V. Woolley, A. A. Forastiere, H. G. Taylor, R. B. Weiss

Research output: Contribution to journalArticle

Abstract

We used mitoguazone (500 mg/m 2 iv weekly, with 50-mg/m 2 escalations weekly as tolerated) to treat 22 patients with squamous cell carcinoma of the head and neck which recurred after initial therapy. Nine of 22 (41%) patients responded: two had complete responses and seven had partial responses. Gastrointestinal toxicity and anemia were commonly seen. We conclude that mitoguazone is active in squamous cell carcinoma of the head and neck and should be incorporated into phase III trials.

Original languageEnglish (US)
Pages (from-to)91-92
Number of pages2
JournalCancer treatment reports
Volume67
Issue number1
StatePublished - Apr 14 1983

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II trial of mitoguazone in patients with advanced squamous cell carcinoma of the head and neck'. Together they form a unique fingerprint.

  • Cite this

    Perry, D. J., Crain, S. M., Weltz, M. D., Wilson, J. P., Davis, R. K., Woolley, P. V., Forastiere, A. A., Taylor, H. G., & Weiss, R. B. (1983). Phase II trial of mitoguazone in patients with advanced squamous cell carcinoma of the head and neck. Cancer treatment reports, 67(1), 91-92.